Pfizer has nominated a second compound for clinical development in its collaboration with Coley Pharmaceutical Group. Coley is developing a novel class of drug candidates known as TLR Therapeutics. This second generation drug candidate is expected to complement Pfizer’s ongoing clinical programs for PF-3512676, Coley’s lead therapeutic TLR9 agonist drug candidate, for the treatment of cancer. Under the agreement, Pfizer has exclusive rights to two novel compounds discovered in the...